Cargando…
Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
Intra-lesional chemotherapy for treatment of cutaneous malignancies has been used for many decades, allowing higher local drug concentrations and less toxicity than systemic agents. Here we describe a novel diterpene ester, EBC-46, and provide preclinical data supporting its use as an intra-lesional...
Autores principales: | Boyle, Glen M., D'Souza, Marjorie M. A., Pierce, Carly J., Adams, Ryan A., Cantor, Aaron S., Johns, Jenny P., Maslovskaya, Lidia, Gordon, Victoria A., Reddell, Paul W., Parsons, Peter G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182759/ https://www.ncbi.nlm.nih.gov/pubmed/25272271 http://dx.doi.org/10.1371/journal.pone.0108887 |
Ejemplares similares
-
Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors
por: Miller, Jane, et al.
Publicado: (2019) -
Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes
por: Cullen, Jason K., et al.
Publicado: (2021) -
Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)
por: De Ridder, Thomas R., et al.
Publicado: (2020) -
EBC Pre-Assembly Last Module
Publicado: (2003) -
EBC Cradle + 18 modules Displacement
Publicado: (2003)